Biovica International
2.48 SEK -5.7%Be the first to follow this company
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Revenue
7.29M
EBIT %
-1,740.05 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
BIOVIC B
Daily low / high price
2.465 / 2.785
SEK
Market cap
208.46M SEK
Turnover
125.4K SEK
Volume
50K
Latest videos
Financial calendar
Extraordinary general meeting
15.07.2024
Interim report
12.09.2024
General meeting
17.09.2024
Interim report
12.12.2024
Interim report
13.03.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Anders Rylander Investment AB | 10.7 % | 16.9 % |
Avanza Pension | 6.9 % | 6.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Biovica International AB – Annual report for the financial year 2023/2024 published
Clarification of notice to extraordinary general meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Notice of the Extra General Meeting in Biovica International AB
Redeye: Biovica - Significant growth at less significant absolut levels
Year-end report 2023/2024
![Biovica International, Audiocast with teleconference, Q4, 2020](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ea6e7b3a-ff5c-49c6-8481-c1120fe16799.png)